Moderna's mRNA flu shot earns FDA approval after rollercoaster review

The FDA has approved Moderna's mRNA flu vaccine for adults 50 and older, a first for the technology in seasonal influenza. The decision caps a review that was never routine, even after a unanimous advisory vote in June.

The clinical case was solid. Trials covering nearly 44,000 people showed superior efficacy against existing flu shots and an acceptable safety profile. On the merits alone, approval was defensible.

What made the path treacherous was the political weather. Health Secretary Robert F. Kennedy Jr. has spent his tenure working against vaccination, starting with the cancellation of a paid CDC flu campaign during a season that was killing children at elevated rates. That backdrop turned a straightforward regulatory decision into a test of whether the agency could still follow its own science.

In the end, the FDA did. The approval is a quiet statement that the review process can hold, even when the administration's top health official is openly hostile to the product class. Moderna now has a foothold in the seasonal flu market, and the technology has a second major indication beyond COVID.

The real question is what happens at the point of care. Approval clears the regulatory bar, but uptake will depend on public trust, provider willingness, and whether the political pressure on vaccines eases or intensifies. The science has spoken. The market will now deliver its own verdict.